From Research to Growth: Why the International Life Sciences Sector Is Turning to Austria
9 October 2026
No Comments
In the photo, the inauguration of the Eric Kandel Institute with the Mayor of
Author: Editoriale
Modified Hiv Drug Reverses Vision Loss And Paralysis In Multiple Sclerosis Model
30 September 2026
No Comments
NIH-funded analysis of clinical data also linked similar antiviral drugs to reduced MS A
UCSF Benioff Children’s Hospitals Become the First US Qualified Treatment Center Contracted to Administer Individualized Gene Therapy WASKYRA®
29 September 2026
No Comments
WASKYRA®, the first gene therapy approved in the US to treat Wiskott-Aldrich Syndrome, is
Scientists Develop High-Resolution Molecular Maps Of Alzheimer’s And Related Brain Disorders
24 September 2026
No Comments
NIH-funded effort delivers new insights into symptoms and underlying mechanisms of these conditions to
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
19 September 2026
No Comments
Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20
Researchers Design Bone Marrow-On-A-Chip Model To Study Human Immune Cells
14 September 2026
No Comments
Miniaturized model provides window into production and behavior of long-lived antibody-producing cells in NIH-funded
NET-Fuels: turning biomass residues into renewable fuels and carbon removal pathways
10 September 2026
No Comments
Four years of Horizon Europe research bring an integrated thermochemical and bio-electrochemical pathway towards
Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
10 September 2026
No Comments
AstraZeneca and Daiichi Sankyo’s Enhertu is the first and only HER2-directed medicine to improve
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
9 September 2026
No Comments
AstraZeneca and Daiichi Sankyo’s Datroway is the only TROP2-directed antibody drug conjugate to prolong
U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
8 September 2026
No Comments
NORTH CHICAGO, Ill., May 27, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food